{"Clinical Trial ID": "NCT00089479", "Intervention": ["INTERVENTION 1:", "AC and T", "Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2 repeat every 3 weeks for 4 cycles", "INTERVENTION 2:", "AC then XT", "Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 in (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles"], "Eligibility": ["Incorporation criteria:", "Women between 18 and 70 years of age;", "Adenocarcinoma of the breast;", "Previous invasive breast cancer if diagnosed > 5 years prior to entry into the study;", "No evidence of metastatic disease.", "- Exclusion criteria:", "\u2022 History of a severe hypersensitivity reaction to Taxotere;", "Previous treatment with anthracycline, anthracenedione (mitoxantrone) or taxane;", "fluoropyrimidine (5-fluorouracil) treatment over the last 5 years."], "Results": ["Performance measures:", "[Number of events]", "Number of patients with/without recurrence of breast cancer, or death due to any cause.", "Delay: Period between the date of randomization and the date of the first event, or the last date known to be no event if no event was reported. Patients were followed for an average of 5 years.", "Results 1:", "Title of arm/group: AC then T", "Description of the arm/group: Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Taxotere 100 mg/m^2 repeat every 3 weeks for 4 cycles", "Total number of participants analysed: 1304", "Type of measurement: Number", "Unit of measure: participants Patients presenting an event: 164", "Patients without event: 1140", "Results 2:", "Title of arm/group: AC then XT", "Description of the arm/group: Adriamycin 60 mg/m^2 iv plus Cytoxan 600 mg/m^2 iv repeat every 3 weeks for 4 cycles followed by Xeloda 825 mg/m^2 in (bid) [total daily dose is 1650 mg/m^2] Days 1-14 every 3 weeks for 4 cycles plus Taxotere 75 mg/m^2 iv every 3 weeks for 4 cycles", "Total number of participants analysed: 1307", "Type of measurement: Number", "Unit of measure: participants Patients presenting an event: 140", "Patients without event: 1167"], "Adverse Events": ["Undesirable Events 1:", "Total: 264/1305 (20.23 per cent)", "NEUTROPENIA FEBRILE 118/1305 (9.04 %)", "NEUTROPENIA 10/1305 (0.77%)", "- ANEMIA 0/1305 (0.00 %)", "LEUKOCYTOSIS 2/1305 (0.15%)", "LEUKOPENIA 1/1305 (0.08%)", "PANCYTOPENIA 0/1305 (0.00 %)", "Myocardial INFARCTION 1/1305 (0.08%)", "SUPRAVENTRICULAR TACHYCARDIA 2/1305 (0.15%)", "NON-STABLE ANGINE 0/1305 (0.00 %)", "0/1305 (0.00 %)", "Adverse Events 2:", "Total: 200/1283 (15.59 per cent)", "NEUTROPENIA FEBRILE 80/1283 (6.24%)", "NEUTROPENIA 11/1283 (0.86%)", "ANEMIA 5/1283 (0.39%)", "LEUKOCYTOSIS 0/1283 (0.00 %)", "LEUKOPENIA 0/1283 (0.00 %)", "PANCYTOPENIA 1/1283 (0.08%)", "Myocardial INFARCTION 1/1283 (0.08%)", "SUPRAVENTRICULAR TACHYCARDIA 0/1283 (0.00 %)", "NON-STABLE ANGINE 1/1283 (0.08%)", "1/1283 (0.08%)"]}